Kymera Therapeutics, Inc.
NASDAQ:KYMRBiotechnology
Healthcare
$119.39 +1.67%
+$1.50 today
- Market cap
- $10.19B
- Beta
- 2.03
- P/E (TTM)
- -28.3
- EPS (TTM)
- -$3.23
52W Low $36.65High $103.00
Volume 0.72M
Average 0.58M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$232.89M
FY 2025 · Annual
Investing Cash Flow
-$521.06M
FY 2025 · Annual
Financing Cash Flow
$990.71M
FY 2025 · Annual
+62.7% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (100.22M) | (154.81M) | (146.96M) | (223.86M) | (311.35M) |
| Depreciation & Amortization | 2.4M | 2.98M | 3.57M | 7.37M | 8.31M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 24.97M | 35.48M | 43.12M | 55.01M | 59.9M |
| Change in Working Capital | (61.92M) | (37.62M) | 9.25M | (23.97M) | 15.27M |
| Accounts Receivables | 577K | (2.4M) | (16.23M) | 17.82M | 947K |
| Inventory | 8.71M | 2.4M | 0 | 0 | 0 |
| Accounts Payables | 54K | 253K | 0 | (307K) | (1.97M) |
| Other Working Capital | (71.26M) | (37.88M) | 25.48M | (41.48M) | 16.29M |
| Other Non-Cash Items | 5.83M | 889K | (11.8M) | (9.06M) | (5.02M) |
| Operating Cash Flow | (128.95M) | (153.09M) | (102.83M) | (194.5M) | (232.89M) |
| Capital Expenditures | (1.6M) | (2.84M) | (34.48M) | (12.84M) | (1.45M) |
| Acquisitions (Net) | 5.81M | (20.52M) | 0 | 0 | 0 |
| Purchases of Investments | (456.4M) | (445.97M) | 0 | (901.23M) | (1.01B) |
| Sales of Investments | 358.17M | 469.33M | 0 | 496M | 479.14M |
| Other Investing Activities | (5.81M) | 20.52M | 174.37M | 13.98M | 8.88M |
| Investing Cash Flow | (99.84M) | 20.52M | 139.89M | (404.08M) | (521.06M) |
| Debt Repayment | (849K) | (1.13M) | (76K) | (1.58M) | (1.49M) |
| Common Stock Issued | 243.11M | 149.83M | 0 | 596.62M | 992.21M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 8.02M | 4.3M | 4.27M | 13.81M | 0 |
| Financing Cash Flow | 250.28M | 153M | 4.19M | 608.85M | 990.71M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 21.5M | 20.43M | 41.25M | 10.27M | 236.76M |
| Free Cash Flow | (130.54M) | (155.92M) | (137.31M) | (207.34M) | (234.34M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$311.4M
+ D&A$8.3M
+ Stock-Based Comp$59.9M
+ Deferred Tax$0
+ Working Capital$15.3M
- Other Non-Cash-$5.0M
= Operating Cash Flow-$232.9M
- Capex-$1.4M
= Free Cash Flow-$234.3M
Analysis
FY2025 free cash flow is -$234.3M. FCF conversion is 75.3% of net income. Operating cash flow was -$232.9M, with capex of -$1.4M. The largest bridge item is Stock-Based Comp at $59.9M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Oct 29, 2026 | |
| 10-Q | Quarterly report | Oct 29, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 27, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 1, 2026 | |
| SC 13G/A | SC 13G/A filing | Sep 8, 2026 |
Does KYMR generate free cash flow?
Kymera Therapeutics, Inc. (KYMR) generated -$234.34M of free cash flow in fiscal 2025.
How much operating cash flow does KYMR produce?
Operating cash flow was -$232.89M, before capital expenditures of $1.45M.
Continue the stock analysis
Jump to another research area for this company.